vs
Side-by-side financial comparison of BioNTech SE (BNTX) and PLEXUS CORP (PLXS). Click either name above to swap in a different company.
BioNTech SE is the larger business by last-quarter revenue ($1.5B vs $1.2B, roughly 1.3× PLEXUS CORP). PLEXUS CORP runs the higher net margin — 4.3% vs -1.9%, a 6.2% gap on every dollar of revenue.
BioNTech SE is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
Plex Systems, Inc. is an American software company based in Troy, Michigan. The company develops and markets the Plex Manufacturing Cloud, a software as a service (SaaS) or cloud computing ERP for manufacturing.
BNTX vs PLXS — Head-to-Head
Income Statement — Q3 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.5B | $1.2B |
| Net Profit | $-28.7M | $49.8M |
| Gross Margin | — | 10.2% |
| Operating Margin | -3.1% | 5.3% |
| Net Margin | -1.9% | 4.3% |
| Revenue YoY | — | 18.7% |
| Net Profit YoY | — | 27.5% |
| EPS (diluted) | — | $1.82 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $1.1B | ||
| Q3 25 | $1.5B | — | ||
| Q2 25 | $260.8M | — | ||
| Q3 24 | $1.2B | — | ||
| Q3 23 | — | $1.0B | ||
| Q2 23 | — | $1.1B | ||
| Q4 22 | — | $1.2B | ||
| Q3 22 | — | $1.0B |
| Q1 26 | — | $41.2M | ||
| Q3 25 | $-28.7M | — | ||
| Q2 25 | $-386.6M | — | ||
| Q3 24 | $198.1M | — | ||
| Q3 23 | — | $15.8M | ||
| Q2 23 | — | $40.8M | ||
| Q4 22 | — | $50.5M | ||
| Q3 22 | — | $37.5M |
| Q1 26 | — | 9.9% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q3 24 | — | — | ||
| Q3 23 | — | 8.9% | ||
| Q2 23 | — | 9.4% | ||
| Q4 22 | — | 9.3% | ||
| Q3 22 | — | 9.2% |
| Q1 26 | — | 5.1% | ||
| Q3 25 | -3.1% | — | ||
| Q2 25 | -192.1% | — | ||
| Q3 24 | 0.8% | — | ||
| Q3 23 | — | 2.7% | ||
| Q2 23 | — | 5.2% | ||
| Q4 22 | — | 5.4% | ||
| Q3 22 | — | 4.9% |
| Q1 26 | — | 3.8% | ||
| Q3 25 | -1.9% | — | ||
| Q2 25 | -148.2% | — | ||
| Q3 24 | 15.9% | — | ||
| Q3 23 | — | 1.5% | ||
| Q2 23 | — | 3.7% | ||
| Q4 22 | — | 4.4% | ||
| Q3 22 | — | 3.7% |
| Q1 26 | — | $1.51 | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q3 24 | — | — | ||
| Q3 23 | — | $0.56 | ||
| Q2 23 | — | $1.45 | ||
| Q4 22 | — | $1.76 | ||
| Q3 22 | — | $1.33 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $303.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | — | $1.5B |
| Total Assets | — | $3.4B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $248.8M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q3 24 | — | — | ||
| Q3 23 | — | $253.0M | ||
| Q2 23 | — | $269.7M | ||
| Q4 22 | — | $274.8M | ||
| Q3 22 | — | $276.6M |
| Q1 26 | — | $1.5B | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q3 24 | — | — | ||
| Q3 23 | — | $1.2B | ||
| Q2 23 | — | $1.2B | ||
| Q4 22 | — | $1.1B | ||
| Q3 22 | — | $1.1B |
| Q1 26 | — | $3.2B | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q3 24 | — | — | ||
| Q3 23 | — | $3.4B | ||
| Q2 23 | — | $3.4B | ||
| Q4 22 | — | $3.4B | ||
| Q3 22 | — | $3.2B |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BNTX
Segment breakdown not available.
PLXS
| Asia-Pacific | $652.0M | 56% |
| Americas | $397.0M | 34% |
| Europe, Middle East and Africa | $116.0M | 10% |
